NTRK1 and glioblastoma: Zhang [115] demonstrated that growth factor receptor tyrosine kinase ErbB2 (HER-2)-specific NK-92/5.28.z (second-generation CAR) Potent and selective antitumor activity against GBM cells in vitro and in orthotopic GBM xenograft models, as well as cure and induction of endogenous antitumor immunity after NK-92/5.28.z treatment in immunocompetent mice.